参考文献/References:
[1] Scicali R,Mandraffino G,Scuruchi M, et al. Effects of lipid lowering therapy optimization by PCSK9 inhibitors on circulating CD34+ cells and pulse wave velocity in familial hypercholesterolemia subjects without atherosclerotic cardiovascular disease:real-world data from two lipid units[J]. Biomedicines,2022,10(7):1715.
[2] Basiak M,Kosowski M,Hachula M,et al. Impact of PCSK9 inhibition on proinflammatory cytokines and matrix metalloproteinases release in patients with mixed hyperlipidemia and vulnerable atherosclerotic plaque[J]. Pharmaceuticals (Basel),2022,15(7):802.
[3] Lianou A,Rallis D,Baltogianni M,et al. Biomarkers of cardiovascular disease risk in the neonatal population[J]. J Dev Orig Health Dis,2023,14(2):155-165.
[4] Barale C,Melchionda E,Morotti A,et al. PCSK9 biology and its role in atherothrombosis[J]. Int J Mol Sci,2021,22(11):5880.
[5] Cesaro A,Bianconi V,Gragnano F,et al. Beyond cholesterol metabolism:the pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics,mutations,expression,and perspective for long-term inhibition[J]. Biofactors,2020,46(3):367-380.
[6] Sundararaman SS,D?ring Y,van der Vorst EPC. PCSK9:a multi-faceted protein that is involved in cardiovascular biology[J]. Biomedicines,2021,9(7):793.
[7] Yurtseven E,Ural D,Baysal K,et al. An Update on the role of PCSK9 in atherosclerosis[J]. J Atheroscler Thromb,2020,27(9):909-918.
[8] D’Ardes D,Santilli F,Guagnano MT,et al. From endothelium to lipids,through microRNAs and PCSK9:a fascinating travel across atherosclerosis[J]. High Blood Press Cardiovasc Prev,2020,27(1):1-8.
[9] Malig?ówka M,Kosowski M,Hachu?a M,et al. Insight into the evolving role of PCSK9[J]. Metabolites,2022,12(3):256.
[10] Seidah NG,Prat A. The multifaceted biology of PCSK9[J]. Endocrine Reviews,2022,43(3):558-582.
[11] Puteri MU,Azmi NU,Kato M,et al. PCSK9 promotes cardiovascular diseases:recent evidence about its association with platelet activation-induced myocardial infarction[J]. Life (Basel),2022,12(2):190.
[12] Guo Y,Yan B,Gui Y,et al. Physiology and role of PCSK9 in vascular disease :potential impact of localized PCSK9 in vascular wall[J]. J Cell Physiol,2021,236(4):2333-2351.
[13] Liu S,Deng X,Zhang P,et al. Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines[J]. Cardiovasc Res,2020,116(10):1721-1732.
[14] Milasan A,Dallaire F,Mayer G,et al. Effects of LDL receptor modulation on lymphatic Function[J]. Sci Rep,2016,6:27862.
[15] Ding Z,Wang X,Liu S,et al. PCSK9 expression in the ischaemic heart and its relationship to infarct size,cardiac function,and development of autophagy[J]. Cardiovasc Res,2018,114(13):1738-1751.
[16] Ragusa R,Basta G,Neglia D,et al. PCSK9 and atherosclerosis:Looking beyond LDL regulation[J]. Eur J Clin Invest,2021,51(4):e13459.
[17] Ding Z,Liu S,Wang X,et al.Cross-talk between PCSK9 and damaged mtDNA in vascular smooth muscle cells:role in apoptosis[J]. Antioxid Redox Signal,2016,25(18):997-1008.
[18] Schlüter KD,Wolf A,Schreckenberg R. Coming back to physiology:extra hepatic functions of proprotein convertase subtilisin/kexin type 9[J]. Front Physiol,2020,11:598649.
[19] Mehta JL. Oxidized or native low-density lipoprotein cholesterol:which is more important in atherogenesis?[J]. J Am Coll Cardiol,2006,48(5):980-982.
[20] Ramin-Mangata S,Thedrez A,Nativel B,et al. Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function[J]. Atherosclerosis,2021,326:47-55.
[21] Wu Y,Shi J,Su Q,et al. Correlation between circulating PCSK9 levels and gestational diabetes mellitus in a Chinese population[J]. Front Endocrinol (Lausanne),2022,13:826757.
[22] Shi J,Zhang W,Niu Y,et al. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes:a population-based cohort study[J]. Cardiovasc Diabetol,2020,19(1):209.
[23] Eluwole A,Adedayo A,Tedla F,et al. Plasma PCSK9 predicts microvascular function but not arterial stiffness in African-Americans with well controlled type 2 diabetes[J]. J Transl Sci,2020,7(4):1-9.
[24] Medina-Leyte,Diana Jhoseline et al. Endothelial dysfunction,inflammation and coronary artery disease:potential biomarkers and promising therapeutical approaches[J]. Int J Mol Sci,2021,22(8):3850.
[25] Leucker TM,Gerstenblith G,Sch?r M,et al.Evolocumab,a PCSK9-monoclonal antibody,rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia[J]. J Am Heart Assoc,2020,9(14):e016263.
[26] Gai MT,Adi D,Chen XC,et al. Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors[J]. Sci Rep,2021,11(1):11450.
[27] Itzhaki Ben Zadok O,Mager A,Leshem-Lev D,et al. The effect of proprotein convertase subtilisin kexin type 9 inhibitors on circulating endothelial progenitor cells in patients with cardiovascular disease[J]. Cardiovasc Drugs Ther,2022,36(1):85-92.
[28] Toscano A,Cinquegrani M,Scuruchi M,et al. PCSK9 plasma levels are associated with mechanical vascular impairment in familial hypercholesterolemia subjects without a history of atherosclerotic cardiovascular disease:results of six-month add-on PCSK9 inhibitor therapy[J]. Biomolecules,2022,12(4):562.
[29] Cammisotto V,Baratta F,Simeone PG,et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) beyond lipids:the role in oxidative stress and thrombosis[J]. Antioxidants (Basel),2022,11(3):569.
[30] Momtazi-Borojeni AA,Sabouri-Rad S,Gotto AM,et al. PCSK9 and inflammation:a review of experimental and clinical evidence[J]. Eur Heart J Cardiovasc Pharmacother,2019,5(4):237-245.
[31] 林智海,王正东,李平,et al. PCSK9抑制剂-依洛尤单抗对急性冠状动脉综合征患者血脂谱及血管内皮功能的影响[J]. 河北医学,2021,27(3):508-512.
[32] Maulucci G,Cipriani F,Russo D,et al. Improved endothelial function after short-term therapy with evolocumab[J]. J Clin Lipidol,2018,12(3):669-673.
[33] Ding Z,Liu S,Wang X,et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues[J]. Cardiovasc Res,2015,107(4):556-567.
[34] Dounousi E,Tellis C,Pavlakou P,et al. Association between PCSK9 levels and markers of inflammation,oxidative stress,and endothelial dysfunction in a population of nondialysis chronic kidney disease patients[J]. Oxid Med Cell Longev,2021,2021:6677012.
[35] Qi Z,Hu L,Zhang J,et al. PCSK9 (proprotein convertase subtilisin/kexin 9)enhances platelet activation,thrombosis,and myocardial infarct expansion by binding to platelet CD36[J]. Circulation,2021,143(1):45-61.
[36] Gurbel PA,Navarese EP,Tantry US. Exploration of PCSK9 as a cardiovascular risk factor:is there a link to the platelet?[J]. J Am Coll Cardiol,2017,70(12):1463-1466.
[37] Cammisotto V,Pastori D,Nocella C,et al. PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation[J]. Antioxidants (Basel),2020,9(4):296.
[38] Borén J,Chapman MJ,Krauss RM,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease:pathophysiological,genetic,and therapeutic insights:a consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J,2020,41(24):2313-2330.
[39] Tang ZH,Peng J,Ren Z,et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway[J]. Atherosclerosis,2017,262:113-122.
[40] Leucker TM,Weiss RG,Sch?r M,et al.Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV independent of low-density lipoprotein cholesterol[J]. J Am Heart Assoc,2018,7(19):e009996.
[41] Barkas F,Milionis H,Anastasiou G,Statins and PCSK9 inhibitors:what is their role in coronavirus disease 2019?[J]. Med Hypotheses,2021,146:110452.
[42] Huang L,Li Y,Cheng Z,et al. PCSK9 promotes endothelial dysfunction in sepsis via TLR4/MyD88/NF-κB and NLRP3 pathways[J]. 2023;46(1):115-128.
[43] Tang Y,Li SL,Hu JH, et al. Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes [J]. Cardiovasc Diabetol,2020,19(1):33.
[44] Wu CY,Tang ZH,Jiang L,et al. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway[J]. Mol Cell Biochem,2012,359(1-2):347-358.
[45] Macchi C,Favero C,Ceresa A,et al. Depression and cardiovascular risk-association among Beck Depression Inventory,PCSK9 levels and insulin resistance[J]. Cardiovasc Diabetol,2020,19(1):187.
[46] Breder I,Cunha Breder J,Bonilha I,et al. Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes:EXCEED-BHS3 trial[J]. Ther Adv Chronic Dis,2020,11:2040622320959248.
[47] Bardolia C,Amin NS,Turgeon J.Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol[J]. Front Cardiovasc Med,2021,8:789931.
[48] McKenney JM. Understanding PCSK9 and anti-PCSK9 therapies[J]. J Clin Lipidol,2015,9(2):170-186.
[49] di Minno A,Gentile M,Iannuzzo G,et al. Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy[J]. Thromb Res,2020,194:229-236.
[50] Song L,Zhao X,Chen R,et al. Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes[J]. Cardiovasc Diabetol,2022,21(1):80.
[51] Denis M,Marcinkiewicz J,Zaid A,et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice[J]. Circulation,2012,125(7):894-901.
相似文献/References:
[1]胥雪莲,何川.前蛋白转化酶枯草溶菌素9与动脉粥样硬化[J].心血管病学进展,2016,(1):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
XU Xuelian,HE Chuan.Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(6):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
[2]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[3]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(6):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[4]李天瑜 袁晋青.前蛋白转化酶枯草溶菌素9抑制剂与血小板功能[J].心血管病学进展,2021,(1):17.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
LI Tianyu,YUAN Jinqing.Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors and Platelet Function[J].Advances in Cardiovascular Diseases,2021,(6):17.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[5]孟凡华 付真彦.一种新型的治疗血脂异常的干扰RNA药物Inclisiran[J].心血管病学进展,2021,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
MENG Fanhua,FU Zhenyan.Inclisiran, A New Small Interfering RNA Drug for the Treatment of Dyslipidemia[J].Advances in Cardiovascular Diseases,2021,(6):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
[6]石惠薇 热娜提·肉孜 刘硕霖 吴娜琼.高脂蛋白a血症的相关治疗进展[J].心血管病学进展,2021,(4):297.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
SHI Huiwei,Rinat·Rozi,LIU Shuolin,et al.Lipoprotein(a)-lowering Therapy[J].Advances in Cardiovascular Diseases,2021,(6):297.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
[7]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(6):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
[8]林琳 李京秀 闫娜 刘丹阳 查理 金恩泽.脂蛋白a的治疗现状及研究新方向[J].心血管病学进展,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
LIN Lin,LI Jingxiu,YAN Na,et al.The Therapeutic Status and Research Prospects of the Treatment of Lipoprotein a[J].Advances in Cardiovascular Diseases,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
[9]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(6):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[10]刘杨 陈明.冠心病的治疗新方向——PCSK9抑制剂[J].心血管病学进展,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
New Direction of Coronary Heart Disease TreatmentPCSK9 Inhibitors.E-mailchenmingcq77@163.com[J].Advances in Cardiovascular Diseases,2021,(6):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[11]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(6):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]